Ertapenem versus piperacillin/tazobactam for diabetic foot infections in China: a Phase 3, multicentre, randomized, double-blind, active-controlled, non-inferiority trial
Zhangrong Xu(Chinese PLA General Hospital), Jue Wang, Ju-fang Shen, Xiaodong Yan(Jining Medical University), Xian Yang(Qingdao University), Weijin Gan, Guoyue Yuan(Jiangsu University), Shengmei Mu, Bo-Shao Zhang
Cited by 27
Related Papers
IWGDF/IDSA guidelines on the diagnosis and treatment of diabetes‐related foot infections (IWGDF/IDSA 2023)
|Diabetes/Metabolism Research and Reviews|2023|283
Cost of treating diabetic foot ulcers in five different countries
|Diabetes/Metabolism Research and Reviews|2012|207
Timely blood glucose management for the outbreak of 2019 novel coronavirus disease (COVID-19) is urgently needed
|Diabetes Research and Clinical Practice|2020|205
A cohort study of diabetic patients and diabetic foot ulceration patients in China
|Wound Repair and Regeneration|2015|181
Epidemiology of Type 2 Diabetic Foot Problems and Predictive Factors for Amputation in China
|The International Journal of Lower Extremity Wounds|2015|153